FTT Research, page-141

Below is the screenshot of Directors remuneration section ( page 8) of FTT Annual Report.

'As part of the Company’s focus on preserving its capital, the Directors resolved to not take payment of any fees following the results of the Phase 2 clinical trial. Directors forfeited all fees for the period 1 December 2018 to 31 May 2019. From 1 June 2019 director fees re-commenced at approximately 50% previous rate.'


This shows FTT is not a life style Company for Directors. All of them are highly credible with impressive track records and will be making decisions in the best interest of shareholders. How many ASX listed Companies do we know, Directors not taking salaries for initial 6 months and recommence at approx. 50% of previous rate when Company got over $3 million plus cash sitting in the bank.

Looking forward to attend virtual AGM to get update on the potential acquisition of asset/ assets.

Good luck!